Suchergebnisse - "Tabernero, J"

PubPharm (254)

1

Future care for long-term cancer survivors: towards a new model

enthalten in: Clinical & translational oncology | 2021

von Provencio, M. | Romero, N. | Tabernero, J. | +18

2

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial

enthalten in: Clinical & translational oncology | 2017

von Longo-Muñoz, F. | Argiles, G. | Tabernero, J. | +8

3

Abstract OT2-01-11: Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

enthalten in: Cancer research | 2017

von Oliveira, M. | Baird, R. | van Rossum, A. | +21

4

Reply to the letter to the editor 'Addressing the quality of the ESMO-MCBS' by Del Paggio

enthalten in: Annals of oncology | 2017

von Cherny, N. | Dafni, U. | Bogaerts, J. | +5

5

ESMO-Magnitude of Clinical Benefit Scale version 1.1

enthalten in: Annals of oncology | 2017

von Cherny, N. | Dafni, U. | Bogaerts, J. | +7

6

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers

enthalten in: ESMO open | 2016

von Cherny, N. | Sullivan, R. | Dafni, U. | +8

7

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weeklynab-paclitaxel plus gemcitabine vs gemcitabine alone in patients with metastatic pancreatic cancer

enthalten in: Annals of oncology | 2016

von Chiorean, E. | Von Hoff, D. | Reni, M. | +14

8

Positron Emission Tomography Response Evaluation from a Randomized Phase III Trial of Weeklynab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Patients With Metastatic Adenocarcinoma of the Pancreas

enthalten in: Annals of oncology | 2016

von Ramanathan, R. | Goldstein, D. | Korn, R. | +10

9

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

enthalten in: The British journal of cancer | 2016

von Delaunoit, T. | Varea, R. | Sastre, J. | +6

10

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

enthalten in: The British journal of cancer | 2016

von Delaunoit, T. | Varea, R. | Sastre, J. | +6

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[26]